Xylourgidis et al. (54) demonstrated that MKP-5 expression was increased in IPF-derived lung fibroblasts but not in whole IPF lungs, implying that MKP-5 inhibition serve as a therapeutic target for IPF. This evidence concerns the gene DUSP10 and idiopathic pulmonary fibrosis.